Sa1989 Pharmacokinetics of Infliximab in Pediatric Patients With Moderate to Severe Ulcerative Colitis: Results From a Randomized, Multicenter, Open-Label Phase 3 Study
Omoniyi J. Adedokun(Western University), Jeffrey S. Hyams(Connecticut Children's Medical Center), Joyce Ford, Honghui Zhou(Janssen (United States)), Lakshmi Damaraju(Janssen (Belgium)), Marion Blank(Janssen (United States)), Anne M. Griffiths(University of Toronto), Hugh M. Davis(South College), Cynthia Guzzo(Janssen (Belgium)), Zhenhua Xu(Hebei Medical University), Jewel Johanns(Johnson & Johnson (United States))
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k